Therefore, selective targeting of these markers should be utilised to deliver cytotoxic drugs to CSCs, as one Wnt pathway antagonist (sFRP4) in HNSCC CSCs decreased CD44, ALDH, ABCG2 and ABCC4 drug-resistance expression [122]. This evidence concerns the gene ABCG2 and head and neck squamous cell carcinoma.